Overview

ZYNRELEF for Pain Management in Total Knee Arthroplasty

Status:
Not yet recruiting

Trial end date:
2026-04-01

Target enrollment:
0

Participant gender:
All

Summary

The goal of this randomized controlled trial is to compare opioid medication consumption after surgery for patients who have a total knee replacement. The main questions it aims to answer are: - How well does the study drug control pain in the days after surgery? - Does the study drug reduce the amount of opioid analgesic consumed after surgery? Participants in the study group will undergo a total knee replacement as planned with their surgeon. In addition, be given the study drug, Zynrelef (combination of bupivacaine and meloxicam). Researchers will compare the above to a control group who will have a total knee replace only according to usual standards to see if there are any differences in the amount of a type of pain medication (opioid analgesic) consumed in the days following surgery.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Baptist Health South Florida

Treatments:

Bupivacaine
Meloxicam

Criteria

Inclusion Criteria:

1. Adult patients undergoing primary unilateral total knee arthroplasty [Current
Procedural Terminology Code: 27447]

2. Patients with a diagnosis of primary osteoarthritis [ICD-10 codes: M17.0, M17.10,
M17.11, M17.12]

3. Varus deformity less than 10 degrees

4. Flexion contracture less than 10 degrees

5. Age 35 - 70 years old

6. BMI < 40

7. Patients who are discharged on the same day after the unilateral total knee
arthroplasty procedure

Exclusion Criteria:

1. Inflammatory arthritis

2. Post-traumatic arthritis

3. Valgus deformity

4. Severe varus (> 10 degrees)

5. Severe flexion contracture (> 10 degrees)

6. Overnight or longer hospital stay after surgery

7. Prior surgery on affected knee other than knee arthroscopy for meniscal or cartilage
debridement/repair

8. Creatinine > 1.2

9. Chronic Kidney Disease (CKD) stage 3, 4, 5 or end stage renal disease

10. Uncontrolled Diabetes mellitus (Glycated Hemoglobin > 8.0%)

11. Current liver disease

12. Personal history of depression or anxiety disorder

13. Personal history of Deep Venous Thrombosis (DVT) or Pulmonary Embolism (PE)

14. Narcotic or tramadol use within 2 weeks of the planned procedure

15. Allergy to aspirin, NSAIDS, oxycodone, Tylenol, local anesthetics

16. Walking aid for anything other than the operative joint

17. Contraindication for use of the study drug (as specified by the manufacturer):

- Known hypersensitivity to local amide anesthetics, NSAIDs or study drug
components

- History of asthma, urticaria or other allergic-type reactions to aspirin or other
NSAIDs

18. Patients taking the following medications:

- Amitriptyline

- Nortriptyline

- Gabapentin

- Pregabalin

- Duloxetine (SNRI)

- Des-Venlafaxine (SNRI)

- Cyclobenzaprine

- Baclofen

19. Pregnant or lactating females

20. Patients unable to provide informed consent

21. Subjects who, in the opinion of the Investigator, may be non-compliant with study
schedules or procedures